NCIt definition : A recombinant humanized bispecific antibody directed against both the negative immunoregulatory
human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory
T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3;
TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint
inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3
bispecific antibody LB1410 simultaneously targets and binds to both TIM-3 and PD-1
expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its
physiologic ligands and prevents the activation of PD-1 by its ligands, programmed
cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates
antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis,
which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and
immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific
T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation
and proliferation more than the blockade of either immune checkpoint receptor alone.;
Semantic type(s)